A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Authors:
Open Access
- 5 September 2022
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (11) , 4910-4960
Abstract
Baricitinib is an oral, selective inhibitor of Janus kinase (JAK)1/JAK2 that transiently and reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a number of chronic inflammatory diseases; accordingly, baricitinib has been studied and approved for the treatment of several rheumatological and dermatological disorders, as well as COVID-19. This narrative review summarises and discusses the safety profile of baricitinib across these diseases, with special focus on adverse events of special interest (AESI) for JAK inhibitors, using integrated safety data sets of clinical trial data, and puts findings into context with the underlying risk in the respective disease populations, using supporting literature. We show that rates of infection with baricitinib generally reflected the inherent risk of the disease populations being treated, with serious infections and herpes zoster being more frequent in rheumatic diseases than in dermatological disorders, and herpes simplex being reported particularly in atopic dermatitis. Similarly, rates of major adverse cardiovascular events (MACE), venous thromboembolism (VTE) and malignancies were generally within or below the ranges reported for the respective disease populations, thereby reflecting the underlying risk; these events were therefore more frequent in patients with rheumatic diseases than in those with dermatological disorders, the latter of whom generally had low absolute risk. AESI were usually more common in patients with risk factors specific for each event. When a population similar to that of ORAL Surveillance was considered, the incidence rate of MACE with baricitinib was numerically lower than that reported with tofacitinib and similar to that of tumour necrosis factor inhibitors. No safety concerns were observed in hospitalised patients with COVID-19 who received baricitinib for up to 14 days. Identifying the patterns and likelihoods of AEs that occur during treatment in large groups of patients with different diseases can help the physician and patient better contextualise the benefit-to-risk ratio for the individual patient.Keywords
Funding Information
- Eli Lilly and Company
This publication has 206 references indexed in Scilit:
- Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studiesAnnals of the Rheumatic Diseases, 2012
- Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritisArthritis Care & Research, 2012
- Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2011
- Noncardiac vascular disease in rheumatoid arthritis: Increase in venous thromboembolic events?Arthritis & Rheumatism, 2011
- Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritisArthritis & Rheumatism, 2011
- Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing diseaseArthritis Research & Therapy, 2011
- Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ responseJournal of Allergy and Clinical Immunology, 2011
- Oxidative stress, inflammation, and cancer: How are they linked?Free Radical Biology and Medicine, 2010
- Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007Arthritis & Rheumatism, 2010
- Phenotype of atopic dermatitis subjects with a history of eczema herpeticumJournal of Allergy and Clinical Immunology, 2009